The Board of Directors of J. B. Chemicals & Pharmaceuticals Ltd. approved an additional investment of up to ₹18 crores in its wholly-owned subsidiary, Unique Pharmaceutical Laboratories, FZE located in Dubai. This decision was made at a meeting held on January 7, 2026. The investment aims to support the operational requirements of UPL FZE.
Dubai Subsidiary Investment
J. B. Chemicals & Pharmaceuticals Ltd. has announced a significant financial commitment to bolster its international operations. The board has approved an additional investment of up to ₹18 crores into Unique Pharmaceutical Laboratories, FZE (UPL FZE), its wholly-owned subsidiary based in Dubai.
Strategic Rationale
The primary purpose of this investment is to meet the operational needs of UPL FZE. The funds will be channeled to support the subsidiary’s ongoing activities and potentially expand its capabilities within the region. UPL FZE is involved in medicines trading. As a wholly-owned subsidiary, UPL FZE remains a related party, but the transaction is conducted at arm’s length.
UPL FZE Overview
Unique Pharmaceutical Laboratories, FZE, was established on December 10, 2013, and operates under the regulations of the Jebel Ali Free Zone. The subsidiary’s revenue for the financial year 2024-25 was AED 627,639. The additional investment highlights J.B. Chemicals’ commitment to its international operations and supports the continued growth of its Dubai-based subsidiary.
Source: BSE
